FDA approves Zepzelca: Jazz Pharmaceuticals stock costs EUR 187.18 with Q2 revenue up 15.50 percent

Published on 10/15/2026 at 12:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA approval expands Zepzelca's use in lung cancer care. Jazz Pharmaceuticals stock costs EUR 187.18 on October 15, 2026, with Q2 revenue at USD 1.21 billion.

Approval and operating signals

The FDA approved Zepzelca with Tecentriq for first-line maintenance treatment on October 15, 2026.
Second-quarter revenue reached USD 1.21 billion, up 15.50 percent year over year.
Jazz Pharmaceuticals stock trades at EUR 187.18 at 12:42 p.m. CEST at Lang & Schwarz on October 15, 2026.

JAZZ, IE00B4Q5ZN47, Illustration mit AI erstellt.

Jazz Pharmaceuticals (ISIN IE00B4Q5ZN47) was at EUR 187.18 at Lang & Schwarz on October 15, 2026, at 12:42 p.m. CEST. The FDA approved its Zepzelca and Roche's Tecentriq combination for first-line maintenance treatment of extensive-stage small cell lung cancer, as Economic Times reported on October 15, 2026.

Approval opens a new use

The approval covers adults whose disease has not progressed after initial chemotherapy. The combination is the first and only first-line maintenance treatment for this setting, according to the Economic Times.

The late-stage trial behind the decision showed a 46.00 percent reduction in disease progression and a 27.00 percent reduction in death risk compared with Tecentriq alone. Reimbursement eligibility gives the new indication a commercial path, while uptake by doctors and insurers remains central to revenue conversion.

What does the approval mean for growth?

Jazz's second-quarter revenue reached USD 1.21 billion, up 15.50 percent year over year, while diluted earnings per share were USD 2.78 for the period ended June 30, 2026. Those figures come from the company's second-quarter financial data and are also reported by MarketBeat.

Three dated company developments

On August 31, 2026, Jazz reported positive overall-survival data for Ziihera in first-line HER2-positive advanced gastroesophageal cancer. On September 15, 2026, it completed the USD 820.00 million acquisition of Actio Biosciences. On October 15, 2026, the FDA approved the Zepzelca and Tecentriq combination, according to Jazz Pharmaceuticals and the Economic Times.

Valuation remains tied to execution

Jazz Pharmaceuticals had a USD 13.6 billion market capitalization and a USD 128.80 to USD 266.38 52-week range as of October 14, 2026. The company trades on Nasdaq under JAZZ, and the new approval adds a measurable commercial milestone to a portfolio spanning neuroscience and oncology.

Stock price and investor perspective

The FDA decision adds a new commercial use for Zepzelca, but the financial payoff depends on treatment adoption and reimbursement. Jazz Pharmaceuticals stock was trading at EUR 187.18 at Lang & Schwarz on October 15, 2026, at 12:42 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Jazz Pharmaceuticals stock.